Key Quantitative Figures
- New manufacturing block capacity: 3600 TPA (Tonnes Per Annum) for Xanthine derivatives
- Total Xanthine derivatives capacity post-expansion: 9600 TPA
- This expansion positions Aarti Pharmalabs among the top 3 Xanthine derivatives manufacturers globally
Location and Facility Details
- Plant location: Tarapur Unit 5, MIDC, Plot No. L-28/29/99
- Address: Aarti Pharmalabs Limited, Unit-V, Plot L-28/29/99, Tarapur MIDC, Boisar, Maharashtra, India, Pin 401506
- Facility description: State-of-the-art additional manufacturing block
Regulatory Status
- All necessary permissions and approvals obtained to start the facility
- Filed under Regulation 30 of SEBI (LODR) Regulations, 2015
Management Commentary
Mr. Rashesh Gogri, Chairman of Aarti Pharmalabs, stated: \"This is a significant milestone which represents a big leap forward for our company, expanding our production capabilities and strengthening our ability to serve our business partners. Trial production has been initiated, and the facility will be ramped up for optimum utilization in the next few quarters.\"
Operational Timeline
- Trial production: Initiated
- Full ramp-up: Expected over the next few quarters to achieve optimum utilization
Business Impact
- Expands production capabilities for Xanthine derivatives
- Strengthens ability to serve business partners
- Enhances capability to cater to large customers' needs
- Supports company's growth and capability development
Company Background
Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with global presence. The company specializes in:
- Comprehensive CDMO/CMO services for small molecule drug substances
- Dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products
- Generic APIs and Intermediates
- Xanthine derivatives manufacturing
The company focuses on innovation and sustainability in the pharmaceutical and nutraceutical domain.